Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 10/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766859 | 0.95 | TTK (0.48) | CSF1RLRRK2PDGFRAFLT3AURKA | |
| SCHEMBL4977265 | 0.94 | TTK (0.49) | CSF1RLRRK2MERTKPDGFRAFLT3 | |
| SCHEMBL4975970 | 0.92 | MERTK (0.43) | CSF1RLRRK2MERTKPDGFRAFLT3 | |
| SCHEMBL4979267 | 0.90 | TTK (0.51) | CSF1RLRRK2MERTKTTK | |
| SCHEMBL4974257 | 0.89 | MERTK (0.40) | CSF1RLRRK2MERTKPDGFRAFLT3 | |
| SCHEMBL10270515 | 0.89 | LRRK2 (0.55) | CSF1RLRRK2TTKEGFR | |
| SCHEMBL4766540 | 0.85 | TTK (0.57) | AURKAAURKBTTK | |
| SCHEMBL4767107 | 0.85 | EGFR (0.42) | LRRK2TTKEGFR | |
| SCHEMBL4979254 | 0.85 | TTK (0.58) | LRRK2MERTKPDGFRAFLT3TTK | |
| SCHEMBL4979599 | 0.85 | MERTK (0.51) | CSF1RMERTKTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | CSF1R 4296/4885LRRK2 3245/4885MERTK 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.